Pulmonology Articles

Pulmonology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Degano B et al. – Treatment with the oral dual endothelin receptor antagonist bosentan has been shown to benefit patients with PAH–HIV without adversely affecting the control of HIV infection, and resulted in functional and hemodynamic normalization in ~20% of patients. Other PAH therapies, including prostacyclin analogs, type 5 phosphodiesterase inhibitors, and single endothelin receptor antagonists, have yet to be evaluated in PAH–HIV.

Related Articles

Is pulmonary arterial hypertension really a late complication of systemic sclerosis
Chest, 10/12/09    Relevance Score: 95%

Pulmonary hypertension in pregnancy: two cases and review of the literature
Internal Medicine Journal, 11/11/09    Relevance Score: 87%

Bosentan: A Review of its Use in the Management of Mildly Symptomatic Pulmonary Arterial Hypertension
American Journal of Cardiovascular Drugs, 10/08/09    Relevance Score: 85%

Prevalence of pulmonary arterial hypertension in an Australian scleroderma population: screening allows for earlier diagnosis
Internal Medicine Journal, 10/21/09    Relevance Score: 84%

Right Ventricular Free Wall Pacing Improves Cardiac Pump Function in Severe Pulmonary Arterial Hypertension: a Computer Simulation Analysis
Heart And Circulatory Physiology, 10/20/09    Relevance Score: 84%


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address